Pushkal Garg - 27 Feb 2023 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
CMO & EVP Dev & Med Affairs
Signature
By: /s/ Andrew Mayer, Attorney-in-Fact For: Pushkal Garg
Issuer symbol
ALNY
Transactions as of
27 Feb 2023
Net transactions value
$0
Form type
4
Filing time
01 Mar 2023, 15:22:35 UTC
Previous filing
05 Aug 2022
Next filing
07 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Restricted Stock Units Award $0 +5,724 $0.000000 5,724 27 Feb 2023 Common Stock 5,724 Direct F1, F2, F3
transaction ALNY Stock Option (right to buy) Award $0 +11,850 $0.000000 11,850 27 Feb 2023 Common Stock 11,850 $190.01 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
F2 Represents the time-vested restricted stock unit portion of the reporting person's annual equity award granted in 2023 for 2022 performance. The reporting person also received 11,447 performance stock units as part of their annual equity award that will vest upon the achievement of three specific performance conditions (subject to a one year minimum vesting period), which will be reported on a Form 4 as to the performance stock units allocated to each performance condition if and when each performance condition is met and the performance stock units vest.
F3 The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.
F4 Represents the time-vested stock option portion of the reporting person's annual equity award granted in 2023 for 2022 performance.
F5 The stock option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney